Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,651 recruiting studies in this area right now.
By phase
- Not applicable9,821
- Phase 24,456
- Phase 12,741
- Phase 1/Phase 21,690
- Phase 31,400
- Phase 2/Phase 3281
- Phase 4262
Top conditions
- Breast Cancer1,231
- Cancer660
- Prostate Cancer655
- Colorectal Cancer493
- Lung Cancer426
- Ovarian Cancer340
- Multiple Myeloma330
- Gastric Cancer300
- Pancreatic Cancer294
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor257
- Cervical Cancer231
- Head and Neck Cancer227
- Endometrial Cancer205
- Advanced Solid Tumors195
- Esophageal Cancer193
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University314
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)286
- Mayo Clinic239
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,426
- Texas641
- Arizona511
- Florida449
- Alabama419
- New York411
- Massachusetts339
- Maryland329
- New Jersey268
- Pennsylvania240
Recruiting studies20,651 total
- NCT04997096Recruiting
Exercise during chemo to prevent weakness from low movement
This study tests whether a structured exercise program during chemotherapy can help prevent physical decline (“immobility,” like getting weaker or moving less) in people with certain ovarian or endometrial cancers. If you’re eligible, you may be guided to exercise while receiving standard chemo, and you’ll have blood tests to track changes.
Boston, MassachusettsAges 18 years+ - NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04996017RecruitingPhase 3
Atezolizumab after surgery for malignant pleural mesothelioma
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
Meldola, ITAòYAges 18 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Birmingham, AlabamaAges 18 years+ - NCT04997317RecruitingPhase 1/Phase 2
Lu-177 targeting drug for returning or growing meningioma
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
Basel, Canton of Basel-CityAges 18 years+ - NCT04998669RecruitingPhase 2
Loncastuximab plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
Fort Myers, FloridaAges 18 years+ - NCT04997837RecruitingPhase 3
Adjuvant chemo with or without PD-1 for stomach cancer after surgery
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04999007Recruiting
AI tool to help surgeons decide during rectal cancer surgery
This trial tests an artificial-intelligence support tool that helps surgeons make decisions during surgery for rectal cancer. If you qualify, the tool may be used alongside the surgical team to support safer, more effective care.
Wuhan, HubeiAges 18–85 - NCT05000801Recruiting
DC-AML cells for AML after remission but with relapse risk
This study tests DC-AML immune cells to help people with acute myeloid leukemia (AML) who are in remission but still show signs of leftover cancer cells or relapse risk. It may help the immune system attack AML cells, especially when a stem cell transplant is not an option.
Beijing, Beijing MunicipalityAges 18–70 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT05000697Recruiting
Watch-and-wait or chemo after rectal cancer radiation
This trial studies people with early-to-mid stage distal rectal cancer who may get radiation and chemotherapy, with an option that may include an extra drug (oxaliplatin). It also tests whether some people can safely follow a “watch and wait” plan instead of immediate additional treatment, aiming to reduce overtreatment while keeping cancer control.
Buenos AiresAges 18 years+ - NCT05000827Recruiting
PSMA PET scan to guide lymph node surgery in prostatectomy
This study tests whether a special prostate scan called PSMA PET/CT can help doctors decide which pelvic lymph nodes to remove during prostate surgery. It may improve who needs lymph node surgery by using scan results to guide the operation.
Nijmegen, GelderlandAges 18 years+ - NCT05001477Recruiting
Registry for men receiving TULSA-PRO prostate treatment
This is a study registry that collects information from men who are going to receive TULSA-PRO treatment. It helps researchers understand how the treatment is used and what outcomes people experience.
West Hills, CaliforniaAges 18 years+ - NCT05001087Recruiting
Patient and doctor registry for active multiple myeloma
This study creates a real-world registry (a group database) of people with active, symptomatic multiple myeloma. It helps researchers learn from patients and doctors over time and may support future research and treatment improvements.
Florence, FirenzeAges 18 years+ - NCT05002556Recruiting
Bladder cancer follow-up registry for adults in France
This trial is a real-world registry that collects information during follow-up for certain early-stage bladder cancer. It may help doctors understand how urinary test results relate to recurrence and guide monitoring over time.
Aix-en-ProvenceAges 18 years+ - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT05004116RecruitingPhase 1/Phase 2
Repotrectinib plus chemotherapy for relapsed solid tumors in youth
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
New York, New YorkAges 1–25 - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Tuscaloosa, AlabamaAges 18 years+ - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT05007379Recruiting
Testing new immune cells on breast cancer samples in the lab
This trial studies whether newly made immune cells (“CAR-macrophages”) can attack breast cancer when tested on your tumor samples grown in the lab (“organoids”). If you need surgery or a tumor biopsy as part of your usual care, your sample may be used to test this approach.
LilleAges 18–100 - NCT05008185Recruiting
Nerve interface surgery to reduce hand pain nerve tumors
This trial tests a regenerative nerve device/surgery approach to reduce painful nerve growths (neuromas) after a finger or partial hand amputation. You may qualify if you’re an adult with confirmed, localized neuroma pain and have already tried a 6-week desensitization therapy plan.
Baltimore, MarylandAges 18 years+ - NCT05008497Recruiting
Cancer patients’ health literacy research at a specific hospital
This study looks at patients’ health literacy—how well people understand and use health information—among adults receiving care for cancer. It’s mainly for people who are followed at a particular hospital and who agree to have their medical data used.
ParisAges 18 years+ - NCT05008809RecruitingPhase 3
FIRE-9 trial: chemo after colon cancer metastasis removal
This trial studies whether giving chemotherapy after surgery or ablation (destroying spots of cancer) can improve outcomes in people with metastatic colon or rectal cancer. It compares post-treatment chemotherapy strategies to reduce the chance the cancer comes back.
AmbergAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,651 recruiting oncology studies from the U.S. registry right now, out of 31,668 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.